Brief: Veracyte Secures Medicare Coverage For Truemrd Monitoring Test In Muscle-Invasive Bladder Cancer
15/05/2026 14:02
May 15 (Reuters) - Veracyte Inc VCYT.O: VERACYTE SECURES MEDICARE COVERAGE FOR TRUEMRD MONITORING TEST IN MUSCLE-INVASIVE BLADDER CANCER VERACYTE INC - TRUEMRD MONITORING TEST AVAILABLE FOR ORDER JUNE 1, 2026 Source text: ID:nBw8kv93La Further company coverage: VCYT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina